Cytogen, Inc. · KRX:217330
Cytogen — Investor Presentation (September 2005)
18 slides from Cytogen's investor presentation, Sep 14, 2005
Slide 1: Quadramet Overview
Exhibit 99.1 “Quadramet® William Senior CYTOGENVice F Goeckeler, President, Corp Overview” PhD Operations
Slide 2: Skeleton Introduction: Tumors metastasizing to bone
Skeleton Introduction Tumors Bone Source: Slide #metastases 2Bagi arising is theCM. most from serve Targeting common theasbreast, a secondary oforgan therapeutic prostate, tosite bemyeloma, affected ofagents tumorto by spread, and bone metastatic lung torepresent treat possess cancer metastatic athe
Slide 3: Cancer Incidence, Deaths and Bone Mets
Cancer Incidence Deaths 5-year Newly Sources: 232,090 99% 30,350 Prostate 212,930 88% 40,870 65-75% Breast 172,570 15% 163,510 30-40% Lung 25,690 97% 1,490 60% Thyroid 63,210 6% 13,180 40% Bladder 59,580 16% 7,770 14-45% Melanoma 36,160 64% 12,660 20-25% Renal 15,980 32% 11,300 70-95% Myeloma Slide
Slide 4: Samarium-153 Properties
Half-life Samarium-153 Beta 710 640 Gamma *Maximum Slide keV Particles* # 4Ray (50%) (30%) 46.3energies, 103 Hours 810 keV keVthe (29%) (20%) average beta emission is 233 keV
Slide 5: Quadramet Chemical Structure
Quadramet® 1 N S O P C 53Sm lide # 5 Chemical Structure
Slide 6: Biodistribution: Bone Scan vs Quadramet
Biodistribution (bone 99mTc-MDP Slide Posterior Anterior (Quadramet) 153Sm-EDTMP #scan) 6
Slide 7: Controlled Study Publications
Controlled 114 118 Study 152 Publication: Slide patients, #424Sm10/11 BA-108 BA-106/110 7 Clinical Resche, Serafini, Sartor, variety hormone Studies et. of et. et. refractory al., primary al., al., Urology, Eur. J. Clin. malignancies J.prostate Cancer, 63, Oncol., 5, cancer 940-945 33, 16,10, 4, 158
Slide 8: Quadramet Indication Statement
Indication Quadramet® Slide # 8 Statement is indicated for relief of pain in patients with confirmed osteoblastic metastatic bone lesions that enhance on radionuclide bone scan
Slide 9: Quadramet Features and Benefits
Features Pain Onset Single Duration Reduces Opioid-sparing Mild Transient Sliderelief side #dose 9 and concomitant myelosuppression effects usually relieves Benefits begins pain opioid for within tends aanalgesic median one to resolve week of use16ofweeks within administration in eight patients week
Slide 10: Lessons Learned: Radiopharmaceuticals
Lessons Radiopharmaceuticals Cytogen’s Educate Facilitate Slide # 10 prospective Learned Quadramet actions: users trial, are relegated about usage,the andto unique new end-stage approaches physical use properties largely to paindue management oftoQuadramet, the safety through profile including regis
Slide 11: Lessons Learned: Prior to Cytogen's Reacquisition
Lessons Prior Cytogen’s Introduce Expand Facilitate New Slide clinical to # 11 Cytogen’s sales Learned amedical actions: multidisciplinary development and marketing oncologists reacquisition initiatives infrastructure approach toof Quadramet marketing tailored to treating to through focus to rights
Slide 12: Lessons Learned: Broad Indication, Prostate Data
Lessons While Cytogen’s Communicate New Slide clinical #Quadramet 12 Learned actions: development the role has aofbroad Quadramet initiatives cancer in designed indication, varioustocancers existing generate using data dataexisting isinprimarily cancers clinical other in prostate data thaninprostate
Slide 13: Lessons Learned: Publication and Presentation Interest
Lessons There Cytogen’s Publication New Slide clinical #is13 Learned interest actions: and development presentation among physicians initiatives of existing todesigned understand clinicaltodata generate the regarding role of data Quadramet in repeat various administration incontemporary a contempora
Slide 14: Lessons Learned: Beyond Supportive Care
Lessons Beyond Cytogen’s Leverage New Slide clinical # 14 its Learned the actions: demonstrated development ability to deliver supportive initiatives a highly care designed specific role, there totherapeutic explore is interest theintumoricidal clinical among physicians settings attributes where to
Slide 15: Applying Lessons: Extensive Clinical Development
Applying More During Cytogen’s Slide #than 15 today’s the extensive a dozen Lessons presentations, clinical ongoingdevelopment clinical you willdevelopment hear programs from some are for underway Quaramet of these physicians in also response reflects (highlighted toCytogen’s physician incommitment
Slide 16: Quadramet with Taxanes Clinical Development
Quadramet TAXane-based Docetaxel TAXSAM1 Status Description Trial (European Paclitaxel TAXSAM2 (Northwestern Weekly TAXSAM3 (M Loading TAXSAM4 (Johns Standard (prostate) TAXSAM5 (Memorial Phase Paclitaxel, (breast) TAXSAM6 (University IRB Slide Dreview #Anderson IIHopkins I/II 16 docetaxel dose doce
Slide 17: Quadramet with Bisphosphonates and Gemcitabine
Quadramet SAMarium Bisphosphonate (prostate) SAMBIS1 (University Bisphosphonates (myeloma) SAMBIS2 (Mayo GEMcitabine Gemcitabine (osteo) GEMSAM1 Status Description Trial (M Phase D Anderson I/II Clinic) Clinical Sm-153 ofwith and Maryland Cancer (zoledronic with SAMarium Quadramet Development lexidr
Slide 18: Quadramet with Velcade and Neoadjuvant Therapy
VELcade® VELSAM1 (Mayo (myeloma) VELSAM2 NEOadjuvant review IRB (Multicenter) Quadramet (osteo) NEOSAM1 Status Description Trial (Johns Neoadjuvant (prostate) NEOSAM2 (Thomas Phase Slide #I/II Hopkins Clinic 17Jefferson 18 Clinical plus for and Quadramet, –use the physician SAMarium Hospital) bortez